(9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
Star0
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- 9(S)-HODE
Commonly known or available as (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid - DrugBank Accession Number
- DB07302
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 296.4449
Monoisotopic: 296.23514489 - Chemical Formula
- C18H32O3
- Synonyms
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- 9S-Hode
- alpha-Dimorphecolic acid
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism APeroxisome proliferator-activated receptor gamma inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as lineolic acids and derivatives. These are derivatives of lineolic acid. Lineolic acid is a polyunsaturated omega-6 18 carbon long fatty acid, with two CC double bonds at the 9- and 12-positions.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- Sub Class
- Lineolic acids and derivatives
- Direct Parent
- Lineolic acids and derivatives
- Alternative Parents
- Long-chain fatty acids / Hydroxy fatty acids / Unsaturated fatty acids / Secondary alcohols / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Alcohol / Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Fatty acid / Hydrocarbon derivative / Hydroxy fatty acid / Long-chain fatty acid / Monocarboxylic acid or derivatives
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- (10E,12Z)-9-HODE (CHEBI:34496) / Other Octadecanoids (C14767) / Other Octadecanoids (LMFA02000188)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 42KE04U9BM
- CAS number
- 73543-67-6
- InChI Key
- NPDSHTNEKLQQIJ-UINYOVNOSA-N
- InChI
- InChI=1S/C18H32O3/c1-2-3-4-5-6-8-11-14-17(19)15-12-9-7-10-13-16-18(20)21/h6,8,11,14,17,19H,2-5,7,9-10,12-13,15-16H2,1H3,(H,20,21)/b8-6-,14-11+/t17-/m1/s1
- IUPAC Name
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- SMILES
- CCCCC\C=C/C=C/[C@@H](O)CCCCCCCC(O)=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0004670
- KEGG Compound
- C14767
- PubChem Compound
- 5312830
- PubChem Substance
- 99443773
- ChemSpider
- 4472255
- ChEBI
- 34496
- ChEMBL
- CHEMBL1230670
- ZINC
- ZINC000004655401
- PDBe Ligand
- 9HO
- PDB Entries
- 2vsr / 8hqn
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00322 mg/mL ALOGPS logP 5.88 ALOGPS logP 5.19 Chemaxon logS -5 ALOGPS pKa (Strongest Acidic) 4.68 Chemaxon pKa (Strongest Basic) -1.6 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 57.53 Å2 Chemaxon Rotatable Bond Count 14 Chemaxon Refractivity 90.03 m3·mol-1 Chemaxon Polarizability 37.23 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9935 Blood Brain Barrier + 0.8153 Caco-2 permeable + 0.7403 P-glycoprotein substrate Substrate 0.526 P-glycoprotein inhibitor I Non-inhibitor 0.958 P-glycoprotein inhibitor II Non-inhibitor 0.7879 Renal organic cation transporter Non-inhibitor 0.9265 CYP450 2C9 substrate Non-substrate 0.8011 CYP450 2D6 substrate Non-substrate 0.8869 CYP450 3A4 substrate Non-substrate 0.6359 CYP450 1A2 substrate Inhibitor 0.704 CYP450 2C9 inhibitor Non-inhibitor 0.9132 CYP450 2D6 inhibitor Non-inhibitor 0.9424 CYP450 2C19 inhibitor Non-inhibitor 0.9359 CYP450 3A4 inhibitor Non-inhibitor 0.9015 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8944 Ames test Non AMES toxic 0.9701 Carcinogenicity Non-carcinogens 0.7204 Biodegradation Ready biodegradable 0.8471 Rat acute toxicity 1.5862 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9332 hERG inhibition (predictor II) Non-inhibitor 0.8619
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0udi-4930000000-e1186c721ea6fb1169c7 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-01t9-2290000000-7710ffea9973c23faa90 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0090000000-9b848ffe645dde50d0ef Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-002b-0490000000-65028010300d01aec6fe Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0019-7940000000-cc10b218077843ffb366 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0671-2690000000-84aa211dcdb5100a5d9a Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-05o1-9210000000-f225ef553650c5d0a89b Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 205.1050301 predictedDarkChem Lite v0.1.0 [M-H]- 211.2508301 predictedDarkChem Lite v0.1.0 [M-H]- 186.71123 predictedDeepCCS 1.0 (2019) [M+H]+ 206.4893301 predictedDarkChem Lite v0.1.0 [M+H]+ 210.8758301 predictedDarkChem Lite v0.1.0 [M+H]+ 189.06924 predictedDeepCCS 1.0 (2019) [M+Na]+ 204.2977301 predictedDarkChem Lite v0.1.0 [M+Na]+ 211.1178301 predictedDarkChem Lite v0.1.0 [M+Na]+ 195.16243 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated pro-inflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of BMAL1 in the blood vessels (By similarity)
- Specific Function
- alpha-actinin binding
- Gene Name
- PPARG
- Uniprot ID
- P37231
- Uniprot Name
- Peroxisome proliferator-activated receptor gamma
- Molecular Weight
- 57619.58 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at September 15, 2010 21:20 / Updated at August 26, 2024 19:22